Implanted Cardioverter Defibrillator Articles & Analysis
14 news found
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISCs with the ...
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. The Board of Directors tapped Dr. Fain to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development ...
Longer-term follow up results from the MODERATO II study presented at the American College of Cardiology conference in May 2021, but not included in JAHA publication, showed that BackBeat CNT reduced oSBP in treated ISH patients by an average of 16.4 mmHg after 18 months of treatment. 1BIS Research, 2017, Global Pacemaker and Implantable Cardioverter ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, Associate Director, Cardiovascular Center ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report documenting the clinical utility of the Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) device leads in a patient with obstructed central veins. ...
(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...
Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform ...
Today, most people with VT are treated with implantable cardioverter defibrillators (ICDs), which monitor the heart rhythm and deliver a strong shock to the heart muscle to correct irregular pacing. ...
WALTHAM. Mass.. May 19,2020 - Thermedicak a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT): today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program is intended to help ...
WALTHAM, Mass., May 8, 2020 - Thermedicak a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today. Called the Saline Enhanced Radiofrequency ...
The WiSE system works together with a previously implanted pacemaker or implantable cardioverter defibrillator (ICD) that paces the right side of the heart. ...
CHICAGO, May 12, 2017 - A new study examines the effectiveness of the Implantable Subcutaneous String Defibrillator (ISSD™), a flexible, string-shaped and first-ever rechargeable implantable cardioverter-defibrillator (ICD). ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that the U.S. Patent and Trademark Office allowed two new patents that include, COATINGS FOR THE CONTROLLABLE RELEASE OF ANTIMICROBIAL METAL IONS and BONE IMPLANT AND SYSTEMS THAT CONTROLLABLY RELEASES SILVER. The Company also announced that they will make the OrthoFuzIon Antimicrobial Bone Screw System ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that the U.S. Patent and Trademark Office issued Patent No. 8,999,367 as a continuation of patent No. 8,927,004 that significantly enhances the claims for the release of antimicrobial metal ions to prevent infection. Paul Chirico, President and CEO of Silver Bullet Therapeutics stated, “We take a lot ...